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ta.2013.0Abstract Background: Hypopharyngeal cancer is a rare disease representing about 0.5% of all
human malignancies and constituting only 3–5% of all head and neck cancer. Concurrent radioche-
motherapy has been recommended as a standard of care in patients with locally advanced squa-
mous cell head and neck carcinomas. There were very few reports about these tumors arising
from North Africa.
Objecttive: This work was a retrospective study at the Ain Shams University hospitals compar-
ing induction chemotherapy and concomitant radiochemotherapy to surgery followed by radiother-
apy as regards over all survival.
Methods: This study included 49 patients with hypopharyngeal carcinoma, twenty-three
(46.93%) were treated surgically. Surgical excision of the tumor was by pharyngo-laryngo-esopha-
gectomy, except for 2 patients treated by conservative surgery. Postoperative radiotherapy was
given to all patients. Twenty sex patients (53.07%) were treated by induction chemotherapy and
concomitant radiochemotherapy.
Results: The mean age was 52.6 years (range 25–82). In the present study, females (55.1%) dom-
inated males (44.9%).The most commonly involved subsite, in this study, was the postcricoid area
(31 patients = 63.3%), followed by the pyriform sinus (16 patients = 32.6%), while the posterior
pharyngael wall was the site of origin in only two patients (4.1%). According to the AJCC-B Ben Sender Street, Saray
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176 M.S. Taha et al.TNM staging system, 40 patients (81.6%) were advanced stages III and IV, while only 9 patients
(18.4%) had an early presentation as stages I and II. Cox proportional-hazard regression was used
to compare survival in the two study groups. There was no statistically signiﬁcant difference in the
failure function (death) between patients treated with concomitant radiochemotherapy or surgery
followed by radiotherapy after adjusting for the age category, tumor grade, T stage and N stage
(proportional hazard, 1.114; 95% CI, 0.574 to 2.163; P, 0.751).Of the variables included in the
model, only N1 stage was an independent predictor for the hazard of death after adjusting for
the treatment group, age category, tumor grade and T stage (proportional hazard, 2.321; 95%
CI, 1.073–5.022; P, 0.033). The model had a 2 log likelihood (likelihood ratio statistic, LRS) of
277.316, which was not statistically signiﬁcant (P, 0.0501) indicating adequate ﬁt of the full model.
Conclusion: Postcricoid carcinoma comprises the majority of hypopharyngeal tumors in Egypt.
Females are more commonly affected by these tumors, especially postcricoid carcinoma. There was
no survival difference between the intended therapy for organ preservation and radical surgery
groups. Patients who received concurrent radiochemotherapy had a better chance of survival with
a preserved larynx compared with patients who underwent surgery.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Ear, Nose, Throat and
Allied Sciences.1. Introduction
Hypopharyneal carcinoma is rare with an incidence of 1 in
100,000 in UK. Sweden has an excellent national cancer data-
base and reported just over 2000 cases of this cancer over a
period of 30 years with a tumor speciﬁc ﬁve year survival of
13%.1 In the UK post cricoid carcinoma makes up around
40%, the pyriform fossa accounts for between half and two
thirds with less than 10% originating on the posterior pharyn-
geal wall.2,3 The hypopharyngeal carcinoma has the poorest
prognosis of any head and neck carcinoma.2 The etiology
of hypopharyngeal tumors has not been extensively studied.4,5
The most important risk factor is the excessive consumption
of alcohol.6 The risk of combined high alcohol intake and
smoking was multiplicative.7 Patients diagnosed with hypo-
pharyngeal carcinoma are typically men aged 55–70 years.
One exception is an increased incidence of postcricoid carci-
noma (PCC) in women aged 30–50 years with Plummer Vin-
son or Paterson–Kelly syndrome.8,9 Currently in the United
States, because of the reduced incidence of the Plummer–Vin-
son syndrome, postcricoid carcinoma is more common in
men.
Nearly all tumors of the hypopharynx are malignant and
most are squamous cell carcinoma, with 70% moderately or
well differentiated tumors.10 The cardinal symptoms and signs
are dysphagia, hoarseness of voice, sore throat, otalgia and
weight loss with or without a lump in the neck. Hypopharyn-
geal carcinoma often presents at an advanced stage, as the
hypopharynx is a silent area allowing tumors to attain ad-
vanced stages before symptoms occur. Other causes contribut-
ing to its poor prognosis are: tendency for submucosal spread,
early metastasis to the regional lymph nodes and tendency to
direct extension to adjacent structures in the neck.8,11,12
Hypopharyngeal carcinoma may be treated by surgery or
an organ preservation protocol. Choice of resection and recon-
struction technique will depend on patient and surgeon’s pref-
erence and expertise, tumor size and location within the
hypopharynx. External beam radiotherapy with concurrent
chemotherapy, rather than radiotherapy alone improves the
laryngeal preservation rate in patients with resectable disease
and results in a survival beneﬁt for those with resectable andnon-resectable disease.13,14 Survival is comparable to laryngo-
pharyngectomy and postoperative radiotherapy.15
The aim of this study was to compare the results of deﬁni-
tive concurrent radiochemotherapy (CRCT) and surgery fol-
lowed by radiotherapy regarding overall survival of patients
with hyopharyngeal carcinoma.2. Patients and methods
This is a retrospective study of all patients with hypopharyngeal
carcinoma, who presented to the Ain Shams University hospi-
tals, Cairo, Egypt, in the period between October 2005 to April
2012. The records of these patients were reviewed to collect the
demographic data, special habits, presenting symptoms and
signs. Endoscopic data, biopsy results and available imaging
were also collected. The study was approved by the Institu-
tional Research Ethics Board of the Ain Shams University.
The patients were then divided into two groups: group I or
surgical group with post operative radiotherapy and group II
or organ preservation protocol group receiving (CRCT). The
surgical details and complications were reviewed as well as
the post-operative radiotherapy sessions received in group I.
In group II, the details of chemotherapy regimen and radio-
therapy sessions were collected. The follow-up record regard-
ing survival was compared.3. Statistical methods
Statistical analysis was done on a personal computer using
MedCalc version 12.2.1.0 statistical package (MedCalc
Software, Mariakerke, Belgium).
Normality of quantitative data distribution was tested using
the Shapiro–Wilk goodness-of-ﬁt test. Normally distributed
quantitative data were presented as mean (standard deviation)
and between-group differences were compared parametrically
using the independent samples Student’s t test. Qualitative data
were presented as ratio or number (percentage) and differences
between the two groups were compared using the Pearson’s chi
square test with the application of Fisher’s exact test when
appropriate.
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survival in the two study groups. Besides the treatment group,
other variables expected to inﬂuence survival were included in
the model to adjust for their effect on the failure function of
interest (i.e., death). These covariates included age, tumor
grade (differentiation), T stage, and N stage. Since our study
included 49 failure events (i.e., deaths), we included only ﬁve
predictors in the regression model in line with the rule that
to avoid over ﬁtting of the model, only one predictor should
be included in a survival model for at least 10 failure events.16
All reported P values are two tailed. P< 0.05 is considered
statistically signiﬁcant.
4. Results
A total of 69 patients’ records with hypopharyngeal carcinoma
were found. Only 49 patients were included in this study, as the
remaining 20 patients did not complete their treatment in ourTable 1 Demographic data.
Variable Surgery group
(n= 23)
Age (yr) 48.5 (10.4)
Male/Female 10/13
Smoker/Non-Smoker 11/12
Data are presented as mean (SD) or ratio.
Table 2 Tumor pathology data.
Variable Surgery group
(n= 23)
Site of tumor
Postcricoid 11 (47.8%)
Piriform fossa 11 (47.8%)
Posterior pharyngeal wall 1 (4.3%)
T stage
T1 1 (4.3%)
T2 7 (30.4%)
T3 12 (52.2%)
T4 3 (13%)
N stage
N0 10 (43.5%)
N1 9 (39.1%)
N2 4 (17.4%)
AJCC staging
Stage I 1 (4.3%)
Stage II 3 (13%)
Stage III 13 (56.5%)
Stage IV 6 (26.1%)
Tumor grade
Grade 1 (well diﬀerentiated) 5 (21.7%)
Grade 2 (moderately diﬀerentiated) 14 (60.9%)
Grade 3 (poorly diﬀerentiated) 4 (17.4%)
Data are presented as number (%).center or were lost for follow up. Females were more
common than males with a male to female ratio of 3:4.
Twenty-four patients were smokers, all were males except for
two females. No single patient was an alcohol consumer
(Table 1).
All patients were pathologically diagnosed as squamous cell
carcinoma, 57.1% had moderately differentiated, and 32.7%
had well differentiated, while only 10.2% had poorly differen-
tiated carcinoma.
The most commonly involved subsite, in this study, was the
postcricoid area (31 patients = 63.3%), followed by the pyri-
form sinus (16 patients = 32.6%), while the posterior pharyn-
geal wall was the site of origin in only two patients (4.1%)
(Table 2). Females comprised 21 (67.7%) patients with postcri-
coid carcinoma, while males were only 10 (32.3%), Pyriform
fossa tumor was found in 10 (62.5%) males and in 6 (37.5%)
females (Table 2). The age ranged from 25 to 82 years
(mean = 52.6 years). The incidence of this tumor was foundRadiochemotherapy group P value
(n= 26)
56.5 (16.7) 0.047
12/14 0.851
13/13 0.879
Radiochemotherapy group P value
(n= 26)
0.064
20 (76.9%)
5 (19.2%)
1 (3.8%)
0.062
3 (11.5%)
5 (19.2%)
7 (26.9%)
11 (42.3%)
0.743
14 (53.8%)
8 (30.8%)
4 (15.4%)
0.419
2 (7.7%)
3 (11.5%)
9 (34.6%)
12 (46.2%)
0.153
11 (42.3%)
14 (53.8%)
1 (3.8%)
Figure 2 Post-operative dye study with passage of contrast
without leak.
178 M.S. Taha et al.to be 28.6% in those below 40 years and 71.4% in those above
40 years.
According to AJCC-TNM staging system,17 33 (67.4%) pa-
tients were staged T3 and T4, while 16 (32.6%) patients pre-
sented as stages T1 and T2. Twenty-ﬁve patients (51%) had
clinically palpable lymph nodes (17 N1 & 8 N2), while 24
patients (49%) had no clinically palpable lymph nodes at the
time of diagnosis.
Forty patients (81.6%) had advanced stages III and IV,
while only 9 patients (18.4%) had an early presentation as
stages I and II.
The two patients with posterior pharyngeal wall tumor,
presented as T4 N0 and T3N2 with a ﬁnal stage IV. No patient
of the 49 included in this series had distant metastasis at the
time of diagnosis.
Group I included 23 (46.9%) patients .Ten patients (43.4%)
were males and 13 (56.6%) were females (Mean
age = 48.5 ± 10.4). Post-cricoid carcinoma (PCC)was diagnosed
in 11 (47.8%)patients,while 11 (47.8%)hadpyriform fossa tumor,
and one (4.3%) patient had posterior pharyngeal wall tumor.
Five (21.7%) patients had well differentiated tumor, 14
(60.9%) had moderately differentiated tumor and 4 (17.4%)
had poorly differentiated tumor (Table 2). 8 (34.7%) patients
had early T1 and T2 tumor, while 15 (65.3%) had late T3
and T4 stages. 10 (43.5%) patients were N0, 9 (39.1%) were
N1 and 4 (17.4%) were N2. The ﬁnal staging in this group
was one patient (4.3%) with stage I, 3 patients (13%) with
stage II, 13 patients (56.5%) with stage III, and 6 patients
(26.1%) with stage IV.
Total pharyngo-laryngo-esophagectomy was done in 21
cases with subsequent reconstruction by mobilization of the
stomach through the posterior mediastinum to allow stomach
pull-up for pharyngo-gastric anastomosis (Fig. 1). Two pa-
tients with early stage had total laryngectomy and partial phar-
yngectomy with primary pharyngeal repair. Neck dissection
was done in 13 patients with clinically positive nodes.Figure 1 Layered anastomosis between the stomach and upper
pharyngeal mucosa.All patients were admitted to the ICU postoperatively for
three days. Patients were allowed to swallow after a gastrogra-
phin swallow- done to them 10 days to 2 weeks postoperatively
showing no anastomotic leak (Fig. 2). Operative mortality oc-
curred only in one patient (4.3%) who died on the table due to
an unrepairable posterior tracheal tear during mediastinal
dissection.
Post-operative unilateral pleural effusion occurred in 5
(21.6%) patients but only two of them required the insertion
of chest drains. Anastomotic leak high in the neck, occurred
in two cases (8.7%), and settled spontaneously by conservative
treatment and compression without further complications.
Two patients developed neck hematoma and one of them
necessitated surgical evacuation. Two patients developed dys-
phagia after 3 months of starting oral feeding and required
the dilatation of a stricture at the pharyngo-gastric anastomo-
sis. Discomfort due to reﬂux of gastric content was noted in 12
(52%) patients during follow-up .Chest infection occurred in 8
(34.8%) patients and resolved after proper antibiotic treat-
ment. Electrolytes disturbance in the form of resistant hypo-
kalaemia for 3 days, was noted in 6 (26%) patients and was
corrected before the patients were discharged from the hospi-
tal. Two patients developed severe depression that required
psychotherapy sessions and anti-depressive medications.
Postoperative (2–4 weeks) radiotherapy was given to all 23
patients in a dose of 60–66 Gy fractionated as 200 cGy/day for
5 days/week along 6–7 weeks. Spinal cord shield was used after
50 Gy.
Group II included 26 patients who received CRCT. Twelve
patients (46.1%) were males and 14 (53.9%) were females
(mean age = 56.5 ± 16.7). Twenty (76.9%) of them were
diagnosed as PCC, 5 (19.2%) had pyriform fossa tumor and
1 patient (3.8%) had posterior pharyngeal wall tumor. Eleven
(42.3%) patients had well differentiated tumor, 14 (53.8%) had
moderately differentiated tumor and 1 (3.8%) had poorly dif-
ferentiated tumor (Table 2). 8 (30.7%) patients had early T1 &
Figure 3 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the two treatment
groups.
Figure 4 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the age categories. No
statistically signiﬁcant difference in overall survival between
patients aged more than 40 years and those aged 40 years or less
after adjusting for the treatment group, tumor grade, T stage and
N stage (proportional hazard, 1.173; 95% CI, 0.527 to 2.61; P,
0.698).
Table 3 Cox proportional hazard model.
Covariate b SE Wald P value Exp(b) 95% CI of Exp(b)
lower bound Upper bound
Treatment with radiochemotherapy 0.108 0.340 0.101 0.751 1.114 0.574 2.163
Age > 40 years 0.159 0.410 0.150 0.698 1.173 0.527 2.610
Diﬀerentiation
Grade 2 tumor -0.031 0.337 0.008 0.927 0.970 0.502 1.872
Grade 3 tumor -0.029 0.607 0.002 0.962 0.972 0.298 3.171
T stage
T2 stage -0.827 0.660 1.568 0.211 0.438 0.121 1.585
T3 stage -0.649 0.610 1.132 0.287 0.523 0.159 1.717
T4 stage 0.552 0.641 0.742 0.389 1.736 0.498 6.055
N stage
N1 stage 0.842 0.396 4.525 0.033 2.321 1.073 5.022
N2 stage 0.835 0.504 2.740 0.098 2.304 0.862 6.157
Overall model ﬁt
Null model -2 Log Likelihood 294.231
Full model -2 Log Likelihood 277.316
Chi-square 16.915
DF 9
P value 0.0501
95% CI, 95% conﬁdence interval; b, regression coefﬁcient; DF, degrees of freedom; Exp(b), proportional hazard; SE, standard error; Wald,
Wald Chi-square statistic.
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patients were N0, 8 (30.8%) were N1 and 4 (15.4%) were N2.
This group included 2 patients (7.7%) with stage I, 3 patients
(11.5%) with stage II, 9 patients (34.6%) with stage III and 12
patients (46.2%) with stage IV.
Prior to deﬁnitive chemoradiotherapy (CRT) comprehen-
sive evaluation was done for all patients. This included speech
and swallowing evaluation, comprehensive dental evaluation
and cleaning, blood laboratory investigations, as well as eval-
uation of the nutritional status and its stabilization. Chemo-
therapy was given in the form of cisplatin 80 mg/m2 in day 1
as a short infusion and 5- ﬂuorouracil 1000 mg/m2 daily from
day 1 to 4 as a continuous infusion after appropriate hydrationand preparation. This course was repeated after 4 weeks and
radiotherapy initiated after 2 weeks of the 2nd cycle. Concur-
rent weekly cisplatin 25 mg/m2 was administered during the
course of irradiation.
All patients were treated by conventional fractionated
course of radiotherapy (2D) over 6–7 weeks, with treatment
delivered once per day, 5 days per week, with 2 Gy daily frac-
tions. Treatment was given using 6 MV linear accelerator pho-
ton beamwhile 9 MeV electron beamwas used only to boost the
Figure 5 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the different tumor
grades. No statistically signiﬁcant difference in overall survival
among patients with different tumor grades after adjusting for the
treatment group, age category, T stage and N stage.
Figure 6 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the different tumor sites.
No statistically signiﬁcant difference was seen in overall survival
among patients with different sites after adjusting for the
treatment group, age category, tumor grade and N stage.
180 M.S. Taha et al.clinically gross lymph nodes. Due to the high likelihood of sub-
clinical nodal metastases, even in the clinically N0 neck, all
patients received comprehensive radiation to encompass nodal
regions from the skull base to clavicle. Two laterally opposed
portals encompassing the primary tumor and upper neck
lymphatics as well as one anterior lower neck ﬁeld were used
for most of the patients while two lateral portals down to the
clavicle were used only in patients in whom the shoulder permits
these ﬁelds. Treatment involves a shrinking ﬁeld technique at
46 Gy to exclude the cervical part of the spinal cord, as well
as ﬁnal mucosal ﬁeld reduction after 54–60 Gy and posterior
neck boosting with electrons to complete the nodal dosing with-
out excessive dose to the spinal cord. The superior border of the
lateral ﬁelds usually included base of skull, while the lowerborder was at the lower aspect of the cricoid cartilage unless
extensive caudal tumor extension. The posterior border is
placed behind vertebral spinous processes (or further if required
to cover metastatic cervical lymph nodes) while the anterior
border ﬂashes the skin at the level of the thyroid cartilage .Gross
nodal disease received 66–70 Gy while prophylactic lymphatic
irradiation was limited to 50 Gy. All the patients who com-
pleted their course of treatment were followed clinically every
two weeks and re-evaluated after 6–8 weeks by CT scan as well
as endoscopic assessment and biopsy. All patients (100%)
developed mucositis, 65% of them were WHO grade 1–2, while
35% were WHO grade 3–4. Management strategy included
oral hygiene and optimal pain control. Seventeen (65.7%)
patients developed transient dysphagia mostly due to post–
radiotherapy edema. Four (15.3%) patients required multiple
dilatations due to stenosis of the post cricoid region and cervical
esophagus.
The endpoint of our study was the overall survival rate .The
duration of survival was deﬁned as the time from the ﬁrst date
of treatment to the date of the event, which was death for the
overall survival rate. The follow up of both groups ranged
from 2 to 84 months.
In group I, 9 (39.2%) patients survived for less than
6 months, 4 (17.4%) patients survived for less than 12 months,
5 (21.7%) patients survived for less than 24 months and 5
(21.7%) survived for more than 24 months (details of over
all survival of group 1).
Meanwhile, in group II, 11(42.3%) patients survived for
less than 6 months, 5 (19.2%) patients survived for less than
12 months, 6 (23%) patients survived for less than 24 months
and 4 (15.5%) patients survived for more than 24 months (de-
tails of over all survival of group 2).
Cox proportional-hazard regression was used to compare
survival in the study groups (Table 3). There was no statisti-
cally signiﬁcant difference in overall survival between patients
treated with concurrent radiochemotherapy or surgery after
adjusting for the age category, tumor grade, T stage and N
stage (proportional hazard, 1.114; 95% CI, 0.574–2.163;
p= 0.751) (Fig. 3).
At the same time there was no statistically signiﬁcant differ-
ence in overall survival in both groups between patients aged
more than 40 years and those aged 40 years or less after adjust-
ing for the treatment group, tumor grade, T stage and N stage
(proportional hazard, 1.173; 95% CI, 0.527–2.61; P, 0.698)
(Fig. 4).
Regarding tumor differentiation, there is no statistically sig-
niﬁcant difference in survival among patients with different tu-
mor grades, and tumor site in both groups after adjusting
other factors in both study groups (Figs. 5 and 6).
There was no statistically signiﬁcant difference in overall
survival among patients in both groups with different T stages
after adjusting for the treatment group, age category, tumor
grade and N stage (Fig. 7).
The Cox model yields that the N1 stage was the only inde-
pendent predictor for the hazard of death after adjusting for
the treatment group, age category, tumor grade and T stage
(proportional hazard, 2.321; 95% CI, 1.073–5.022; P, 0.033)
(Fig. 8).
The model had a2 log likelihood (likelihood ratio statistic,
LRS) of 277.316, which was not statistically signiﬁcant
(p= 0.0501) indicating adequate ﬁt of the full model.
Figure 7 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the different T stages. No
statistically signiﬁcant difference was seen in overall survival among
patients in both groupswith different T stages after adjusting for the
treatment group, age category, tumor grade and N stage.
Figure 8 Survival curves produced by Cox proportional hazard
regression. Distinct curves are plotted for the different N stages.
N1 stage was the only independent predictor for the hazard of
death after adjusting for the treatment group, age category, tumor
grade and T stage (proportional hazard, 2.321; 95% CI, 1.073–
5.022; P, 0.033).
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Hypopharyngeal carcinoma has the worst prognosis among all
head and neck tumors. Patients tend to present with loco-
regionally advanced disease, with one-half of patients having
nodal metastasis at diagnosis.18
Almost 81.6% of our patients presented with stage III and
IV disease and 51% had lymph node metastases, which con-
tributed largely to the advanced stage of the disease. The over-
all survival rates of these tumors vary from 10 to 60%.19–21
The conventional treatment for locally advanced but resectable
head and neck cancers has been surgery with post-operative
adjuvant therapy. A huge progress in non-surgical organ pres-
ervation treatment for all head and neck cancer has been donein the last two decades, demonstrating that laryngeal preserva-
tion by different CRT protocols is a safe alternative for pa-
tients with T2–T4 tumors. Based on these encouraging
results, CRCT as the deﬁnite treatment for advanced head
and neck cancer has been studied in the past 15 years, includ-
ing cancers arising from the hypopharynx.22
The ideal treatment strategy for the management of hypo-
pharyngeal cancer is still unclear and the management of lo-
cally advanced disease, however, varies by institution.
In the literature only few studies are available to compare
different treatment protocols in the treatment of speciﬁc sub-
sites such as the hypopharynx. This study was intended to
compare the overall survival in patients with hypopharyngeal
cancer treated by CRCT versus surgery followed by
radiotherapy.
The incidence of this tumor in the present study was found
to be only 28.6% in those below 40 years in comparison to
71.4% in those above 40 years. This result agrees with most
of the reports.12 However there were reports that showed that
the incidence of this tumor was found to be nearly the same in
those below 40 years, and those above the same age.23,24 Saleh
et al.,25 study of Upper Egypt showed two peaks of age among
their patients: 13–35 years and 56–60 years.
Females were about 55.1% of the patients, while males
were only 44.9%. Postcricoid carcinoma remains the only
squamous head and neck cancer that is more common in wo-
men.12,26 Most of patients in the present study were postcricoid
carcinomas (63.4%), and so the female predominance can eas-
ily be understood.
Different studies, however, reported a male dominance in
all cases of hypopharyngeal carcinoma.27–29 This can be ex-
plained by the fact that, most of the studies reporting males
to be more affected, have the pyriform sinus as the main sub-
site of affection with rare cases from the postcricoid area.
None of our patients was an alcohol consumer, a ﬁnding
that can be explained by religious reasons. At the same time,
smoking was found in only 48.9% of our patients, mostly
men. As the postcricoid area was found to be the most com-
mon subsite in this study, and hence the large number of fe-
males, this caused a lower rate of smoking, which is still for
social and cultural reasons less in females.
The relatively small percentage of smokers, and the absence
of alcohol consumption among patients in this study, points that
these two predisposing factors are not strongly involved in hyp-
opharyngeal carcinoma in Egypt. This should raise our atten-
tion to shift to different predisposing factors such as dietary
factors or malnutrition that can be particularly important in
esophageal and postcricoid cases in malnourished areas of the
world, and can be commonly found in our patient’s population.9
The operative mortality (2%) of such a major surgery in
these cases was acceptable and comparable to other series with
even higher percentage.23,24,30
The different treatment regimens used in the two groups did
not signiﬁcantly differ with respect to overall survival. In the
literature there are various comparisons between the surgical
and organ preservation protocols, with none showing a signif-
icant improvement regarding the overall survival of one
modality over the other.20,28,31–34 Some studies even showed
slightly improved outcome with a primary surgical procedure,
but still not signiﬁcant, as shown in our results.19,35–37
The shift to organ preservation protocols worldwide, are
mainly due to improved laryngopharyngeal preservation in
182 M.S. Taha et al.such cases. However, one should not miss that these protocols
have high toxicity rate and need intensive patient care and
monitoring by experienced multi-disciplinary teamwork. Opti-
mizing the compliance of CRCT while keeping adequate treat-
ment dose remains challenging for advanced hypopharyngeal
carcinoma. Moreover, the functional sparing of the laryngo-
pharynx is not always granted with such protocols. Treat-
ment-related toxicity, the need for permanent gastrostomy
tube placement and overall preservation of laryngoesophageal
function remains low.38
Successful CRCT laryngeal preservation for advanced hyp-
opharyngeal carcinoma remains difﬁcult to achieve and should
be performed with caution. The importance of detailed pre-
treatment counseling cannot be overstated.
N1 stage was the only independent predictor for the hazard of
death. This agrees with the study conducted by Jones,12 who re-
ported that patients with N0, N2a and N2b disease have a 38%
5-year survival, while N1 neck disease had a 20% 5-year survival
rate. It is not clear why larger nodes can be better prognostically,
however, the pathological node stage is still the most accurate
method of assessing prognosis in head and neck carcinoma.6. Conclusion
Postcricoid carcinoma comprises the majority of hypopharyn-
geal tumors in Egypt. The majority of these patients present at
late stage with lymph node metastases. Patients who received
CRCT had an equal chance of survival with a preserved larynx
compared with patients who underwent surgery. We suggest
that organ preservation intended therapy should be considered
for patients with advanced hypopharyngeal carcinoma. The
criteria for selecting patients who will respond to and complete
the treatment remain key issues for future investigation .At the
same time, functional and quality of life determination are
essential to include in future evaluation of such protocols.
7. Conﬂict of interest
None declared.
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